Loading stock data…
Prelude Therapeutics Incorporat (PRLD)
$5.30-0.16 (-2.93%)
Market ClosedLast close Sep 8
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prelude Therapeutics Incorporated in the Healthcare sector is trading at $5.30 with a market capitalization of $344M. Wall Street consensus targets $8.00 (3 analysts), implying a +50.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $6.83, remaining 45.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.58M↓ | $5.64M↓ | $6.50M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.18M↑ | -$17.35M↑ | -$20.42M↑ | -$32.19M↑ | -$34.61M |
| Net Income | -$10.38M↑ | -$16.46M↑ | -$19.73M↑ | -$31.23M↑ | -$32.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$344.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-129.27%
Volume
Today's trading volume
257,583
Recent News
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity. On May 12, […]
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...